This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Amarendra Pegu, Ph.D.
Head, Antibody Research at NIAID/NIH


I have been studying the use of monoclonal antibodies to prevent or treat HIV-1 infection by using the NHP model since the past 10 years. We have shown that some of the most broad and potent anti-HIV-1 antibodies that have been recently identified can be used for prevention and treatment of viral infection using nonhuman primate models of HIV-1 infection. Based on these data, the best monoclonal antibodies have been down selected for testing in clinical trials to evaluate their use in both prevention and treatment of HIV-1 infection. I have also been involved in developing novel bi- and tri-specific antibody-based proteins that can be used to prevent or treat HIV-1 infection. These projects have included extensive collaborations with partners from both academia and industry. Overall, our goal is to develop novel antibody-based therapies that can be used in prophylactic and therapeutic strategies against HIV-1.

Agenda Sessions

  • Developing Bi-/tri-specific Antibodies for Prevention and Treatment of HIV-1 Infection